WO2007057399A3 - Treatment of cancer with indole derivatives - Google Patents

Treatment of cancer with indole derivatives Download PDF

Info

Publication number
WO2007057399A3
WO2007057399A3 PCT/EP2006/068461 EP2006068461W WO2007057399A3 WO 2007057399 A3 WO2007057399 A3 WO 2007057399A3 EP 2006068461 W EP2006068461 W EP 2006068461W WO 2007057399 A3 WO2007057399 A3 WO 2007057399A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
indole derivatives
indolinones
mek1
Prior art date
Application number
PCT/EP2006/068461
Other languages
French (fr)
Other versions
WO2007057399A2 (en
Inventor
Wolfgang Sommergruber
Norbert Kraut
Norbert Schweifer
Wolfgang Rettig
Frank Hilberg
Flavio Solca
Martin Steegmaier
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Wolfgang Sommergruber
Norbert Kraut
Norbert Schweifer
Wolfgang Rettig
Frank Hilberg
Flavio Solca
Martin Steegmaier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Wolfgang Sommergruber, Norbert Kraut, Norbert Schweifer, Wolfgang Rettig, Frank Hilberg, Flavio Solca, Martin Steegmaier filed Critical Boehringer Ingelheim Int
Publication of WO2007057399A2 publication Critical patent/WO2007057399A2/en
Publication of WO2007057399A3 publication Critical patent/WO2007057399A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention is based on the finding that indolinones are useful for the therapy of diseases which result from aberrant activity of a kinase selected from the group comprising AXL, FLT3, MEK1, and RET.
PCT/EP2006/068461 2005-11-15 2006-11-14 Treatment of cancer with indole derivatives WO2007057399A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05110778 2005-11-15
EP05110778.7 2005-11-15

Publications (2)

Publication Number Publication Date
WO2007057399A2 WO2007057399A2 (en) 2007-05-24
WO2007057399A3 true WO2007057399A3 (en) 2007-08-30

Family

ID=35695754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/068461 WO2007057399A2 (en) 2005-11-15 2006-11-14 Treatment of cancer with indole derivatives

Country Status (1)

Country Link
WO (1) WO2007057399A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220224A4 (en) * 2007-11-09 2012-02-01 Wayne John Cancer Inst Utility of ret mutant in diagnosis and treatment of melanoma
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
CN102994616B (en) * 2011-09-13 2014-06-18 益善生物技术股份有限公司 MEK1 gene mutation detection specificity primer and liquid chip thereof
US8933103B2 (en) 2012-01-31 2015-01-13 Daiichi Sankyo Company, Limited Pyridone derivatives
TWI723572B (en) 2014-07-07 2021-04-01 日商第一三共股份有限公司 Pyridone derivatives containing tetrahydropyranylmethyl group and use thereof
KR102649887B1 (en) 2014-11-16 2024-03-22 어레이 바이오파마 인크. Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
TN2018000027A1 (en) 2015-07-16 2019-07-08 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
ES2896079T3 (en) 2016-02-26 2022-02-23 Ono Pharmaceutical Co Drug for cancer therapy, characterized by the administration of the combination between an Axl inhibitor and an immune checkpoint inhibitor
MX2018012163A (en) 2016-04-04 2019-07-08 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrro lidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide.
EP3439663A1 (en) 2016-04-04 2019-02-13 Loxo Oncology Inc. Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
JP7443057B2 (en) 2016-05-18 2024-03-05 ロクソ オンコロジー， インコーポレイテッド (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine -1-Preparation of carboxamide
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
JP7156287B2 (en) 2017-08-23 2022-10-19 小野薬品工業株式会社 Cancer therapeutic agent containing an Axl inhibitor as an active ingredient
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
JP7223998B2 (en) 2017-10-13 2023-02-17 小野薬品工業株式会社 Solid cancer therapeutic agent containing an Axl inhibitor as an active ingredient
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052869A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
WO2000073297A1 (en) * 1999-05-27 2000-12-07 Boehringer Ingelheim Pharma Kg Substituted indolinone as tyrosine kinase inhibitors
WO2002036564A1 (en) * 2000-11-01 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors
WO2004009546A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004009547A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004017948A2 (en) * 2002-08-16 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of lck inhibitor for treatment of immunologic diseases
WO2006067175A1 (en) * 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2007054551A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052869A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
WO2000073297A1 (en) * 1999-05-27 2000-12-07 Boehringer Ingelheim Pharma Kg Substituted indolinone as tyrosine kinase inhibitors
WO2002036564A1 (en) * 2000-11-01 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors
WO2004009546A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004009547A1 (en) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in position 6, production and use thereof as medicaments
WO2004017948A2 (en) * 2002-08-16 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of lck inhibitor for treatment of immunologic diseases
WO2006067175A1 (en) * 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2007054551A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors

Also Published As

Publication number Publication date
WO2007057399A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007057399A3 (en) Treatment of cancer with indole derivatives
UA98629C2 (en) Compounds and methods for kinase modulation
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
LTC1830843I2 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
IN2014KN02886A (en)
NO2012017I1 (en) Benzimidazole derivative, process for its preparation, drug containing this compound and use of the compound.
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
EA200970447A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
IS2722B (en) 1, 2, 3, 4- Tetrasetin indole for the treatment of respiratory diseases
DK2054418T3 (en) Dihydrothienopyrimidines as AKT protein kinase inhibitors
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
NL1029045A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth.
WO2006075256A3 (en) 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity
WO2006078865A3 (en) Direct racemization of indole derivatives
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
PL1843771T3 (en) Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
NO20080037L (en) Combination of Pyrimidylaminobenzamide Compounds and Imatinib for the Treatment or Prevention of Proliferative Diseases
NO20082130L (en) 3-Amino-1-arylpropylindoles and aza-substituted indoles
WO2007002087A3 (en) Cdc6s as modifiers of the pten/akt pathway and methods of use
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
MX2007007496A (en) Indole derivatives with antitumor activity.
WO2005010148A3 (en) Marks as modifiers of the pten pathway and methods of use
WO2006099182A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06829994

Country of ref document: EP

Kind code of ref document: A2